Role of the Kallikrein-kinin System in Septic Cardiomyopathy

NCT06080282 | Completed DMC

• 1 other identifier: TJ-IRB202308109
• Study Type: observational
• Target: 567
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate whether there are differential expressions of molecules in the kallikrein-kinin system (KKS) pathway in septic cardiomyopathy, and to analyze their regulatory mechanisms and gene expression changes.

Conditions

Sepsis

Keywords

sepsis; Septic cardiomyopathy; KKS

Outcome Measures

Primary Outcomes (1)

• Survival

  Survival

  28 days

Secondary Outcomes (1)

• Cardiac function

  24 hour

Study Arms (2)

Sepsis

No intervention

Controls

Non-septic controls

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Critical ill patients without sepsis; Patients with sepsis and patients diagnosed with septic cardiomyopathy.

You may qualify if:

• (1) Age range greater than 18 years. (2) Patients diagnosed with septic cardiomyopathy. (3) Clear determination of the cause of myocardial injury, such as the source of infection, bacterial culture results, etc. (4) Patients who are capable of cooperating and completing the necessary examinations and treatments.

You may not qualify if:

• (1) Presence of other significant underlying cardiovascular diseases, such as coronary heart disease, heart failure, etc. (2) Presence of other organ dysfunction that poses a significant threat to life, such as respiratory failure, liver failure, etc. (3) Presence of severe infections or inflammatory diseases unrelated to myocardial injury, such as severe acute pancreatitis. (4) History of receiving interventional treatments, such as immunomodulatory agents, anti-inflammatory drugs, etc. (5) Pregnant or lactating women. (6) Pediatric patients who are under the age of majority.

Sponsors & Collaborators

• Qin Zhang: lead

Study Sites (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Excess blood from patient blood gas analysis, followed by separation of plasma.

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• QIN Zhang, phd

  Tongji Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 28 Days
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: phd

Study Record Dates

• First Submitted: October 6, 2023
• First Posted: October 12, 2023
• Study Start: June 1, 2017
• Primary Completion: October 14, 2024
• Study Completion: October 14, 2024
• Last Updated: March 30, 2026

Record last verified: 2026-03

Locations

CN (1)